Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

2024-516625-31-00 Protocol DS8201-801 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 25 Nov 2025 · Status Ongoing, recruiting · 2 EU/EEA countries · 8 sites · Protocol DS8201-801

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 76
Countries 2
Sites 8

Advanced Solid Tumor

Key facts

Sponsor
Daiichi Sankyo Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
25 Nov 2025 → ongoing
Decision date (initial)
2025-10-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516625-31-00
ClinicalTrials.gov
NCT07015697

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumor

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Daiichi Sankyo Inc.

Sponsor organisation
Daiichi Sankyo Inc.
Address
211 Mount Airy Road
City
Basking Ridge
Postcode
07920-2311
Country
United States

Scientific contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Public contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Locations

2 EU/EEA countries · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 10 4
Spain Ongoing, recruiting 15 4
Rest of world
Taiwan, Japan, Brazil, United States, Korea, Republic of
51

Investigational sites

France

4 sites · Ongoing, recruiting
Centre De Lutte Contre Le Cancer Eugene Marquis
Oncology, Avenue La Bataille Flandre Dunkerque, Cs 44229, Rennes Cedex
Institut De Cancerologie De L Ouest
Medical Oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Centr Georges Francois Leclerc
Early Phase Unit - Medical Oncology, 1 Rue Professeur Marion, 21000, Dijon
Centre Francois Baclesse
Service de Pathologie Mammaire, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5

Spain

4 sites · Ongoing, recruiting
Hospital Clinic De Barcelona
Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2026-01-22 2026-05-13
Spain 2025-11-25 2026-01-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-10 Spain Acceptable
2025-10-30
2025-10-30
2 SUBSTANTIAL MODIFICATION SM-1 2026-01-20 Spain Acceptable
2026-04-13
2026-04-14
3 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-22 Acceptable
2026-04-13
2026-04-22